Clinical Trial

Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2024 (before its estimated November 11, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to investigate the effects of ECMO-assisted therapy on L-AmB PK parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of L-AmB in the ECMO population. To establish and validate a population pharmacokinetic model for liposomal amphotericin B in patients with critically ill patients of invasive fungal infections treated with ECMO adjuvant therapy, and to explore the pharmacokinetics/pharmacodynamics of the drug with different dosing regimens.
Trial Details
NCT Number NCT06754436
Lead Sponsor Beijing Anzhen Hospital
Conditions Invasive Fungal Infections, Liposomal Amphotericin B
Enrollment 30 participants
Start Date 2025-01-10
Primary Completion 2025-11-11 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-31